Amal Therapeutics, a Geneva, Switzerland-based biotech developing peptide-based therapeutic cancer vaccines, completed the second closing of its €29M Series B financing round.
The round was co-led by Boehringer Ingelheim Venture Fund, with participation from BioMedPartners and Helsinn Investment Fund with VI Partners, Schroder Adveq and High-Tech Gründerfonds.
The second and final tranche of €21.2m (CHF 24.2m) brings the total round to just over €29m (CHF 33.2m).
The company will use the funds to progress its lead vaccine (ATP128) toward clinical development and proof-of-concept in colorectal cancer. The clinical trial is expected to start in summer 2019. In addition, Amal will further develop its proprietary technology Kisima, a self-adjuvanting protein-based immunization platform capable of producing single therapeutic vaccines for immunotherapy and beyond.
Led by Dr Madiha Derouazi, CEO and founder, Amal Therapeutics is a pre-clinical stage biotechnology company developing peptide/protein-based therapeutic vaccines with a focus on oncology.
The company’s therapeutic vaccines are based on its versatile proprietary technology platform called KISIMA®.
Its lead programme, ATP128, is a therapeutic protein vaccine for metastatic colorectal cancer. The program is expected to enter phase I clinical trials in 2019.